logo-loader
viewOncimmune

Oncimmune Hldngs PLC - Director/PDMR's Dealing

RNS Number : 0419P
Oncimmune Holdings PLC
05 June 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Director/PDMR's Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, was informed that, on 4 June 2020, dealings in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by the following Director / PDMRs had occurred:

 

-       Meinhard Schmidt, Non-Executive Chairman, together with his wife and PCA, Tatiana Schmidt, acquired in aggregate 13,000 Ordinary Shares at a weighted average price of £1.885 per share

 

-       Tim Bunting, Non-Executive Director, acquired 150,000 Ordinary Shares at a weighted average price of £1.192 per share

 

-       Adam Hill, Chief Executive Officer, acquired 8,481 Ordinary Shares at a price of £1.179 per share

 

-       Matthew Hall, Chief Financial Officer, acquired 1,272 Ordinary Shares at a price of £1.179 per share

 

-       Ron Kirschner, General Counsel and Company Secretary, acquired 1,652 Ordinary Shares at a price of £1.204 per share

 

 

Director/PDMR/ PCA

No. of Ordinary Shares acquired

Resulting interest

Resulting % holding

Meinhard Schmidt / Tatiana Schmidt

13,000

31,000

0.05%

Tim Bunting

150,000

2,956,717

4.7%

Adam Hill

8,481

40,913

0.06%

Matthew Hall

1,272

11,935

0.02%

Ron Kirschner

1,652

1,652

0.003%

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Meinhard Schmidt / Tatiana Schmidt

2

 

Reason for the notification

a)

 

Position/status

 

Non-executive Chairman / PCA

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£1.17

8,000




£1.21

5,000







d)

 

Aggregated information




- Aggregated volume

13,000 shares

Weighted average price of £1.885



- Price




e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Timothy Bunting

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£1.195

60,000




£1.19

90,000







d)

 

Aggregated information




- Aggregated volume

150,000 shares

Weighted average price of £1.192



- Price




e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Dr Adam Mark Hill

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£1.179

8,481







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

 

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Matthew Hall

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£117.9

1,272







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Ron Kirschner

2

 

Reason for the notification

 

a)

 

Position/status

General Counsel and Company Secretary

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£1.204

1,652







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHSSWESLESSEFM

Quick facts: Oncimmune

Price: 139.5

Market: AIM
Market Cap: £88.6 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20